NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division’s revenues will reach more than $1.5 million per month by year end, well above its breake ...

NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that the company's 2024 Annual Meeting of Shareholders ("Annual Meeting") was convened and adjourned, without any business being conducted, due to lack of the required quorum. Message from Ilan Danieli, CEO: During this process, we've realized that there are quite a few shareholders who didn't know whether their shares were voted on or not. If you are not sure if your shares were v ...

NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted, due to lack of the required quorum. Message from Ilan Danieli, CEO: During this process, we’ve realized that there are quite a few shareholders who didn’t know whether their shares were voted on or not. If you are not sure if your shares were ...

文章核心观点 - 公司正在召集股东投票,以确保明天的股东大会有足够的法定人数 [1][2][3][4] - 公司希望避免因缺乏法定人数而需要推迟股东大会的额外费用,这可能高达10万美元 [3] - 公司是一家专注于癌症诊断的生物技术公司,致力于提高诊断准确性,改善实验室工作流程,最终提高患者预后,降低医疗费用 [5][6] 公司概况 - 公司名称为Precipio,Inc.,是一家专注于癌症诊断的生物技术公司 [5] - 公司在实验室中设计、测试、验证并临床使用创新技术,以改善诊断结果 [5] - 公司将这些技术商业化为专有产品,服务于全球实验室社区,扩大公司的影响力 [6] 财务信息 - 公司未提供任何财务数据或预测 风险因素 - 公司未提供任何风险因素信息

文章核心观点 - 公司的病理学部门收入已经超过了盈亏平衡点,但由于一些运营问题导致收入下降,目前正在解决这些问题,预计下一个季度将重新超过盈亏平衡点 [2][3] - 公司产品部门由于一些技术和供应链问题导致产品发布延迟,但这些问题已经解决,收入增长正在恢复,并有两家大客户即将上线使用公司技术 [4][5] - 公司受到了Change Healthcare遭黑客攻击的影响,导致病理学服务部门现金流受阻,但公司已采取措施通过短期贷款补充现金流,预计在第三季度恢复正常运营 [6][7] - FDA最新的LDT(实验室自主研发检测)监管规定将对公司的病理学服务部门和产品部门产生影响,但公司已制定应对措施,预计不会对公司造成重大财务影响 [8][9][10][11][12][14][15][16] 文章其他要点 业务增长 - 公司病理学部门在2023年第四季度实现了盈亏平衡,现金消耗降至10万美元以下 [2] - 公司产品部门收入增长受到一些技术和供应链问题的影响,但这些问题已经解决,收入增长正在恢复,有两家大客户即将上线使用公司技术 [4][5] Change Healthcare黑客攻击及现金影响 - 公司受到Change Healthcare遭黑客攻击的影响,导致病理学服务部门现金流受阻,但公司已采取措施通过短期贷款补充现金流,预计在第三季度恢复正常运营 [6][7] - 随着收入增长,公司预计现金消耗将逐步减少,有望在今年晚些时候实现盈亏平衡 [7] FDA LDT监管规定 - FDA最新的LDT监管规定将要求实验室自主研发的检测产品进行FDA注册和审批,给公司的病理学服务部门和产品部门带来影响 [8][9] - 对于病理学服务部门,公司现有的检测产品无需额外工作即可"被纳入豁免",未来新增检测产品也可选择FDA批准的产品,不会对公司造成重大财务影响 [10][11][12] - 对于产品部门,公司选择由自身提交产品进行FDA审批,而不是要求客户实验室自行提交,这将为客户减轻负担,并为公司带来竞争优势 [14][15][16] - 公司预计FDA审批过程中的成本约为25万美元 [16]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-1789357 (State or other ju ...

Precipio, Inc. (NASDAQ:PRPO) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statement ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36439 PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware 91-17893 ...

Precipio, Inc. (NASDAQ:PRPO) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking s ...